Diphtheria

What Is Diphtheria?

Diphtheria is a serious bacterial infection caused by Corynebacterium diphtheriae. It most often affects the throat and upper airway, where it can produce a thick grey-white membrane, and toxin-producing strains release a poison that can injure the heart, nerves and kidneys. Treatment combines diphtheria antitoxin, antibiotics, isolation and close medical monitoring, and it begins as soon as the diagnosis is suspected — often before every laboratory result is available.

That urgency is what separates diphtheria from a routine sore throat. An infection that seems ordinary at first can progress within days to painful swallowing, marked neck swelling and narrowing of the airway. The membrane is not loose debris. It is firmly attached tissue that can bleed if disturbed and can physically obstruct breathing. At the same time, the toxin travels through the bloodstream and can begin injuring the heart and nervous system before the throat looks dramatically ill. This is why clinicians treat suspected diphtheria as an emergency rather than waiting for confirmation.

A brief note on spelling, because it matters for anyone researching the condition: the word is frequently typed as diptheria or dithera. Both are common misspellings of diphtheria, and both refer to the same disease described on this page.

What was diphtheria caused by?

Diphtheria is caused by the bacterium Corynebacterium diphtheriae, and specifically by strains that carry the gene for diphtheria toxin. It is the toxin, more than the bacteria themselves, that produces the most dangerous effects: inflammation of the heart muscle, nerve damage and, in some patients, kidney involvement. A closely related organism, Corynebacterium ulcerans, can produce the same toxin and cause a diphtheria-like illness, usually after contact with animals or unpasteurised dairy products. Not every strain produces toxin, which is why laboratories test isolated bacteria for toxin production, not just for the organism itself.

How is diphtheria transmitted?

Diphtheria spreads mainly through respiratory droplets — coughing, sneezing and close face-to-face contact with an infected person. It can also spread through direct contact with infected skin sores in cutaneous diphtheria, and less commonly through objects contaminated by secretions. Some people carry the bacteria in the nose or throat without feeling unwell; these carriers can still pass the infection to others, which is one reason public health teams trace and test close contacts of a confirmed case. Crowded living conditions, incomplete vaccination and disrupted health systems all make transmission easier.

Is diphtheria still around today?

Yes. Diphtheria has become rare in countries with strong childhood vaccination programmes, but it has not disappeared anywhere. The bacteria continue to circulate in parts of Asia, Africa, the Middle East, the Pacific and Eastern Europe, and outbreaks recur wherever vaccination coverage falls — during conflict, displacement, economic disruption or gaps in routine childhood immunisation. Travellers, migrants and unvaccinated or under-vaccinated people in any country remain at risk. Because adult booster protection fades with time, adults in well-vaccinated countries are not automatically protected either.

When was the last diphtheria case in the US?

There is no final “last case” — occasional cases of diphtheria are still identified in the United States, as in other highly vaccinated countries. Respiratory diphtheria became rare in the US after widespread vaccination in the twentieth century, but sporadic cases continue to be reported, most often linked to international travel or to people who were never fully vaccinated. Cutaneous diphtheria is identified somewhat more often than the respiratory form. The practical point is that rarity is not the same as elimination: clinicians in every country are trained to recognise diphtheria precisely because it still appears.

Diphtheria Symptoms

Diphtheria symptoms usually appear two to five days after exposure, though the window can be longer. Early on, the illness can be hard to distinguish from other throat infections: sore throat, low-grade fever, tiredness and loss of appetite. The feature that raises concern is progression — particularly the formation of a membrane in the throat or nose, swelling of the neck, or any change in breathing or voice.

Symptoms of respiratory diphtheria

Respiratory diphtheria affects the throat, tonsils, voice box or nose. You may notice painful swallowing, hoarseness, a grey-white coating over the tonsils or back of the throat, enlarged and tender neck glands, and in more severe cases a so-called “bull neck” appearance caused by soft-tissue swelling. Drooling, noisy breathing (stridor), a barking cough, breathlessness and unusual exhaustion suggest the airway is being affected. The membrane bleeds if it is scraped or pulled, so attempts to remove it outside a controlled medical setting are dangerous.

Symptoms vary considerably between patients. Some people have mild early findings yet remain contagious and still face the risk of toxin-related complications. Others deteriorate quickly, particularly infants, older adults and people with underlying heart, lung or immune conditions. Nasal diphtheria, more common in young children, may cause a persistent, sometimes blood-tinged nasal discharge with crusting around the nostrils, and can look deceptively mild while still spreading infection.

Symptoms of cutaneous diphtheria

Cutaneous (skin) diphtheria typically appears as slow-healing ulcers or sores, sometimes covered by a grey membrane, often on the legs, feet or hands. It is seen more often in tropical regions, in crowded conditions and among people with limited access to hygiene facilities. Skin diphtheria rarely threatens the airway, but it matters for two reasons: the sores can transmit the bacteria to others, and some skin infections involve toxin-producing strains, so the clinical team assesses whether antitoxin is needed rather than assuming it is not.

How Diphtheria Is Diagnosed

Diphtheria is diagnosed through a combination of clinical examination, exposure history and laboratory testing — and because timely treatment matters more than paperwork, clinicians often begin therapy when the diagnosis is strongly suspected rather than waiting for final confirmation.

The assessment usually includes a careful examination of the throat, nose, skin and lymph nodes, measurement of breathing effort and oxygen levels, and detailed questions: vaccination history, recent travel, contact with anyone unwell, and possible links to a known case or outbreak. Swabs are taken from the throat, nose or skin lesions for culture and for specialised testing that identifies Corynebacterium diphtheriae and determines whether the strain produces toxin. Molecular tests can speed up detection in some laboratories, while culture remains important for confirmation and for public health follow-up.

Blood tests help gauge severity — inflammation, hydration, kidney and liver function, and markers of heart muscle injury. An electrocardiogram and continuous cardiac monitoring may be arranged if toxin effects are suspected. Imaging is not always required, but chest imaging or airway assessment is used when pneumonia, airway narrowing or other complications are a concern. In hospital, the diagnostic work is usually shared between infectious disease specialists, paediatricians or internists, intensive care physicians when needed, the microbiology laboratory and public health authorities, because diphtheria is a notifiable disease in most countries.

When Diphtheria Is Suspected, Treatment Is Urgent

Diphtheria is uncommon in many countries because of vaccination, but when it occurs it is treated as a medical emergency. The infection can develop quickly in the throat and upper airway, and the toxin can injure the heart and nerves even while the visible illness still looks moderate. Care therefore begins at the point of suspicion, in the hospital where the patient already is — antitoxin and antibiotics are not delayed for travel, second opinions or completed test results.

For patients and families, the situation can feel frightening. A sore throat becomes severe. A child or adult develops fever, swollen neck glands, hoarseness, noisy breathing or striking weakness. Questions about contagiousness, isolation, vaccination status and travel plans arrive all at once. These concerns are reasonable, and the answer to most of them is the same: diphtheria is managed through coordinated hospital care, infection control precautions and careful monitoring, with public health teams involved from an early stage.

One practical limit is worth stating plainly. Because diphtheria spreads through respiratory droplets and close contact, and because breathing complications can develop rapidly, a person with suspected acute diphtheria is not a candidate for commercial flights or cross-border travel. Where specialised transfer is genuinely needed, it is organised through medical transport channels with infection control planning, under the direction of the treating clinicians and public health authorities — never as routine travel. Second opinions and structured follow-up become relevant after the acute illness is stabilised, not instead of urgent local treatment.

The goals of treatment are consistent everywhere: neutralise circulating toxin, eliminate the bacteria, protect the airway, prevent spread to others and monitor for delayed complications. Early treatment reduces the risk of serious harm, particularly heart inflammation and nerve problems. And even after the throat begins to improve, follow-up continues, because some complications appear days or weeks later.

What Diphtheria Treatment Involves

Diphtheria treatment is not a single procedure. It is a coordinated package of urgent medication, isolation and supportive monitoring, built around four elements: antitoxin, antibiotics, infection control and organ protection.

Diphtheria antitoxin neutralises toxin that is still circulating in the bloodstream. Its limit is important to understand: antitoxin cannot reverse injury the toxin has already caused to tissue. That is precisely why early administration matters, and why clinicians in many suspected cases give antitoxin before final laboratory confirmation — particularly when the patient has a compatible throat membrane, breathing symptoms, neck swelling or signs suggesting toxin effects elsewhere in the body.

Antibiotics eliminate Corynebacterium diphtheriae itself. They stop bacterial growth, shorten the period during which the patient can infect others and support recovery. The choice of drug depends on the patient’s age, allergies, disease severity, local resistance patterns and clinical protocols; macrolide antibiotics and penicillin-based therapy are commonly used options, selected by the treating physician. Antibiotics complement antitoxin — they do not replace it, because they act on the bacteria, not on toxin already released.

Isolation precautions protect everyone around the patient. Care is delivered with droplet and contact precautions until the patient is no longer considered infectious according to medical and public health criteria, which usually involves confirming bacterial clearance. Close contacts — household members, caregivers, classmates, colleagues — may need assessment, preventive antibiotics, swab cultures and a vaccination review, even if they feel entirely well.

Supportive care covers everything the illness demands beyond the two main medications: oxygen, intravenous fluids, pain and fever management, nutrition support and observation in a monitored unit or intensive care setting when breathing, heart rhythm or neurological complications are a concern. In severe cases, airway support becomes necessary if the membrane or swelling threatens breathing, and this is planned in advance by specialists rather than attempted as a last-minute response.

Cutaneous diphtheria is usually less likely to obstruct the airway but still requires antibiotics, thorough wound care and the same infection control discipline. Because some skin infections carry toxin-producing strains, the team evaluates each patient individually and decides whether antitoxin is warranted rather than ruling it out by default.

Who May Need Diphtheria Treatment

Anyone with suspected or confirmed diphtheria needs urgent medical assessment — children and adults alike. The people most at risk of developing the disease are those who were never vaccinated, those who did not complete the full vaccine series and those whose booster protection has faded over the years. Diphtheria also appears in communities where vaccination coverage has been disrupted, and in people exposed through travel, migration, crowded housing or close contact with an infected person.

It is worth repeating that full vaccination does not remove the need for assessment. Vaccinated people who are exposed may develop milder illness, but any suspected case is evaluated properly, because the early signs of significant disease can be subtle and because even mild carriers can transmit the bacteria.

Patient situations that commonly lead to treatment

In practice, treatment decisions cluster around a few recognisable situations:

• A patient with a compatible throat membrane and an incomplete or unknown vaccination history.
• A patient who develops airway symptoms after exposure to a confirmed case.
• A person with a suspicious, slow-healing skin lesion and a positive culture.
• A close contact of a confirmed case who develops any symptoms.
• Close contacts who feel entirely well but need preventive antibiotics, cultures and vaccination updates to interrupt transmission.

The last category surprises many families: healthy-feeling household members may still be asked to take preventive treatment. This is standard practice, because carriers without symptoms can keep the chain of transmission going.

Conditions and Indications Addressed by Diphtheria Care

Diphtheria care addresses both the infection itself and the toxin-related risks that can follow it. The clinical plan is adapted to the type of diphtheria, the patient’s age, the severity of illness and whether complications are already present.

• Respiratory diphtheria: infection involving the throat, tonsils, larynx, nose or upper airway — the form most associated with airway obstruction and toxin-related complications.
• Pharyngeal or tonsillar diphtheria: disease of the throat and tonsils, typically with a thick membrane, sore throat, fever and neck swelling.
• Laryngeal diphtheria: disease of the voice box and airway, which may cause hoarseness, a barking cough, stridor or breathing difficulty, and carries a particular risk of obstruction in small children.
• Nasal diphtheria: infection causing nasal discharge, crusting or bleeding, especially in younger children — often milder in appearance but still contagious.
• Cutaneous diphtheria: skin infection appearing as chronic ulcers, sores or infected wounds, which contributes to transmission and can occur alongside other skin infections.
• Toxin-related complications: myocarditis, abnormal heart rhythms, nerve weakness, swallowing problems, breathing-muscle weakness and kidney involvement.
• Exposure in close contacts: household members, caregivers, healthcare workers and others who need evaluation, preventive antibiotics and vaccination updates.

Because diphtheria is a notifiable infectious disease in most countries, care also involves public health authorities. This is not bureaucracy for its own sake: contact tracing, follow-up testing and vaccination checks are how a single case is prevented from becoming several.

How Diphtheria Treatment Is Performed

Hospital care for diphtheria is organised around three priorities — speed, safety and infection control. The first hours typically follow a recognisable sequence:

1. Assessment of breathing, oxygen levels, heart rate, blood pressure, temperature and hydration.
2. Immediate isolation with droplet and contact precautions.
3. Collection of diagnostic samples — throat, nasal or skin swabs and blood tests — ideally before antibiotics start, provided this causes no delay to urgent care.
4. Administration of diphtheria antitoxin when clinically indicated.
5. Start of antibiotic therapy.
6. Continuous monitoring for airway, cardiac and neurological complications.

Initial assessment and preparation

On arrival, the medical team examines the throat carefully but deliberately avoids disturbing the membrane, because bleeding and airway compromise can follow. If there is severe neck swelling, stridor, drooling, exhaustion or low oxygen levels, airway specialists and intensive care physicians are involved immediately rather than on standby. Isolation begins at the point of suspicion: staff wear protective equipment, the patient is placed in an appropriate room, and family members receive instructions about masks, hand hygiene and limits on contact. For children especially, this separation is emotionally hard — and it is also one of the most effective ways to protect siblings, parents and other patients.

The team also reviews allergies, current medications, immune status and vaccination records at this stage, because each of these shapes decisions about antitoxin, antibiotic choice and monitoring intensity.

Antitoxin administration

Diphtheria antitoxin is the single most important intervention for respiratory diphtheria. It works by binding toxin that has not yet attached to body tissues. Because antitoxin in many settings is derived from animal serum, clinicians assess the risk of allergic reaction and follow established protocols for testing, preparation and administration where required, with emergency medications and monitoring available throughout.

Dose and timing depend on how severe the illness is and how long it has been developing. A patient with an extensive membrane, significant neck swelling, a delayed presentation or signs of systemic toxicity needs more intensive management than someone caught early. Antitoxin decisions are made by experienced clinicians, often in consultation with infectious disease specialists and public health authorities, because access routes and protocols differ from country to country — in some places antitoxin is held centrally and released case by case.

Antibiotic treatment

Antibiotics start promptly and are given orally or intravenously depending on the patient’s condition, ability to swallow and severity of illness. Patients who are very unwell, vomiting, dehydrated or unable to swallow safely usually begin with intravenous therapy and switch later. The prescribed course is completed in full under the direction of the treating team, even when symptoms improve early, and follow-up cultures are commonly required to confirm the bacteria have cleared before isolation ends. If cultures remain positive, the treating doctor extends or adjusts therapy.

Airway, heart and neurological monitoring

Respiratory diphtheria narrows the airway through membrane formation and swelling, so the team watches for increasing work of breathing, stridor, falling oxygen levels and fatigue. Oxygen is provided as needed; in severe cases, airway intervention takes place in a controlled setting with specialists prepared for a difficult airway.

The toxin can also inflame the heart muscle, producing myocarditis or rhythm disturbances. Patients with moderate or severe disease therefore have electrocardiographic monitoring, cardiac enzyme testing, echocardiography or intensive care observation as indicated. Neurological monitoring runs alongside, because toxin-related nerve damage can affect swallowing, eye movement, limb strength or the breathing muscles — and, importantly, these problems can emerge after the throat has started to improve. This delayed pattern is the main reason follow-up is built into diphtheria treatment rather than added on afterwards.

Technology used in diagnosis and monitoring

Modern diphtheria care draws on laboratory and monitoring technology that lets clinicians act quickly and track the disease closely. Microbiology testing identifies the organism and establishes whether it produces toxin; molecular methods can accelerate detection where available, while culture remains essential for confirmation and public health management. Blood tests track inflammation, hydration, kidney and liver function and possible heart involvement. Continuous vital-sign monitoring, pulse oximetry and cardiac rhythm monitoring detect deterioration early. Imaging is added when complications are suspected, and in intensive care, ventilatory support can assist breathing if obstruction or respiratory-muscle weakness develops. None of this replaces clinical judgement; it sharpens it.

How long does hospital care last?

There is no single answer — the length of hospital care varies widely with the form and severity of disease. Mild cutaneous diphtheria needs a different level of care than severe respiratory diphtheria with airway or cardiac concerns. Most patients with respiratory diphtheria remain in hospital until breathing is stable, toxin-related complications have been assessed, antibiotics are established and infectiousness is being managed according to protocol. Recovery then continues at home and in clinic: repeat cultures, cardiac review, neurological assessment, rehabilitation for weakness where needed, nutrition support and vaccination planning. One counterintuitive fact shapes that last item — surviving diphtheria does not reliably produce long-term immunity, so vaccination is usually recommended after recovery.

Why Acting Early Matters

Diphtheria is time-sensitive because toxin injury can progress even while the throat infection appears manageable. Antitoxin works best before the toxin binds to the heart, nerves and other tissues; once binding has occurred, the drug cannot undo it. Delayed care raises the risk of airway obstruction, myocarditis, nerve paralysis, swallowing impairment, aspiration, respiratory failure and death.

Contagiousness is the second reason speed matters. Antibiotic treatment and isolation reduce spread to household members, classmates, colleagues and healthcare staff, and close contacts benefit most when preventive treatment starts quickly — especially contacts who are unvaccinated, partially vaccinated or medically vulnerable.

Delay also complicates diagnosis. Antibiotics taken before samples are collected can make cultures harder to interpret. Clinicians manage this trade-off deliberately: samples are collected as early as possible, but treatment is never withheld simply to preserve a cleaner test result.

Finally, early action means making realistic decisions about travel. A patient with suspected acute diphtheria is assessed and stabilised locally, full stop. Specialised transfer, where genuinely needed, runs through medical transport channels with infection control planning. Evaluation elsewhere — second opinions, complication review, post-acute follow-up — belongs to the phase after stabilisation, when travel is medically appropriate and cleared by the treating team.

Benefits of Diphtheria Treatment

The benefits of treatment fall into five areas: stopping toxin activity, clearing the infection, protecting breathing, catching complications early and reducing transmission.

Benefit	What It Means for You
Neutralises circulating toxin	Antitoxin reduces the amount of toxin still active in the bloodstream, lowering the risk of further injury when given early.
Clears the bacterial infection	Antibiotics eliminate Corynebacterium diphtheriae, support recovery and shorten the period during which you can infect others.
Protects the airway	Close monitoring lets clinicians detect breathing problems early and provide oxygen, airway support or intensive care when needed.
Monitors for heart and nerve complications	Cardiac and neurological observation identifies complications that may require additional treatment or longer follow-up.
Reduces community spread	Isolation, contact tracing and preventive treatment for close contacts protect family members and the wider community.
Supports safer long-term recovery	Structured follow-up, rehabilitation where needed and vaccination planning help patients regain strength and reduce future risk.

Recovery Timeline After Diphtheria Treatment

Recovery depends on the severity of infection, how quickly treatment began, whether complications occurred and the patient’s overall health. The pattern below describes a typical course, not a promise.

Time Period	What Patients Can Expect
Day 1	Urgent assessment, isolation, diagnostic swabs and blood tests. Antitoxin and antibiotics may begin as soon as diphtheria is suspected. Breathing and heart rhythm are monitored closely.
First Week	Throat pain, fever and swelling may begin to settle with treatment, but airway and cardiac monitoring often continue. Isolation remains in place until medical criteria are met.
First Month	Energy returns gradually. Follow-up cultures, cardiac evaluation or neurological assessment may be needed. Some patients need support for swallowing, nutrition or weakness.
Longer Term	Care focuses on monitoring for delayed complications, completing vaccination recommendations and returning safely to school, work or travel after medical clearance.

Factors That Influence Outcomes

The single most important factor is timing: how early appropriate treatment begins. Antitoxin given early in the illness is more likely to limit toxin-related injury. Delayed presentation, extensive membrane formation, significant neck swelling, myocarditis, airway obstruction or neurological involvement all make the illness more complex to manage.

Vaccination history matters too. People who are fully vaccinated may develop milder disease if exposed, although every suspected case still requires proper evaluation. Unvaccinated or incompletely vaccinated individuals face a higher risk of severe infection and complications, and booster status is especially relevant for adults, whose immunity declines with time since the last dose.

The form of diphtheria shapes the treatment plan. Respiratory disease usually demands more intensive monitoring than localised skin disease — but cutaneous diphtheria should not be dismissed, because it transmits the bacteria and can involve toxin-producing strains.

Age and underlying health also influence recovery. Infants, older adults, pregnant patients, people with immune compromise and those with heart, lung or kidney disease need closer observation. Nutritional status, access to timely care and co-infections play their part as well.

Finally, a good result depends on coordination. Infectious disease expertise, careful airway planning, a reliable laboratory, cardiac and neurological monitoring, disciplined infection control and public health liaison all contribute to safer management. Follow-up after the acute phase is part of the treatment itself — not an optional extra — because the most serious complications of diphtheria can appear after the patient starts feeling better.

The Diphtheria Vaccine

The diphtheria vaccine protects against toxin-related disease using a diphtheria toxoid — an inactivated form of the toxin that trains the immune system without causing illness. It is almost always given as part of a combination vaccine rather than on its own, and it remains the reason diphtheria is rare in much of the world today.

What is the diphtheria tetanus and pertussis vaccine?

The diphtheria tetanus and pertussis vaccine is a single combined injection that protects against three diseases at once: diphtheria, tetanus and pertussis (whooping cough). The combinations used against diphtheria — diphtheria-tetanus (Td) and diphtheria-tetanus-pertussis (DTaP for young children, Tdap for older children and adults) — all contain diphtheria toxoid, with formulations adjusted by age. Children typically receive a primary series in infancy and early childhood, followed by boosters; exact schedules vary by country, which is why the treating doctor or national immunisation programme is the reference point for timing.

Is diphtheria tetanus pertussis a tetanus shot?

Yes, in practice it usually is. The “tetanus shot” most adults receive is a combination vaccine — commonly Td or Tdap — that contains tetanus toxoid alongside diphtheria toxoid, and in Tdap the pertussis component as well. This means many adults keep their diphtheria protection topped up without realising it, each time they receive a tetanus booster after an injury or as routine care.

How long does diphtheria tetanus pertussis protection last?

Protection is not lifelong — it fades gradually over the years, which is why boosters exist. Adults are typically advised to have a diphtheria-and-tetanus-containing booster every ten years, with earlier doses sometimes recommended before travel to regions where diphtheria circulates. The pertussis component may be recommended at specific moments, such as during pregnancy, according to national guidance. Because schedules and products differ between countries, booster timing is a conversation to have with your own doctor rather than a rule to apply from a website.

Where can you get a diphtheria tetanus pertussis vaccine?

In most countries, the vaccine is available through general practitioners and family doctors, paediatric clinics, travel medicine clinics, occupational health services and, in many places, community pharmacies. Travellers often use the weeks before a trip to bring routine vaccinations up to date, and a vaccination review is a standard part of preparing for any planned hospital stay; our guide to travel vaccines and infection precautions explains how that review fits into planning.

One further point that surprises many patients: recovering from diphtheria infection does not guarantee lasting immunity. People who have had the disease are usually advised to complete or update their vaccination after recovery, under their doctor’s guidance.

Diphtheria Care at Acibadem

Diphtheria demands the kind of hospital infrastructure that works quietly in the background until it is suddenly essential: isolation-capable rooms, safe specimen handling, laboratory pathways for culture and toxin testing, continuous cardiac monitoring and intensive care capacity for airway support. At Acibadem, care for serious infectious diseases draws on infectious disease physicians, paediatricians and internal medicine specialists, emergency and intensive care teams, cardiologists, neurologists, microbiology laboratories and rehabilitation professionals, working within shared infection control and antibiotic stewardship protocols.

Complex cases are reviewed collaboratively — particularly where there are concerns about myocarditis, airway compromise, neurological weakness or the longer arc of recovery after severe infection. That multidisciplinary structure matters for diphtheria specifically, because the disease crosses specialty boundaries: it begins as an infection, can become a cardiac problem, and may end as a rehabilitation task.

Two things are worth understanding about where diphtheria care happens. The acute illness is treated in the hospital where the patient already is — travel during the acute phase is neither safe nor normally permitted. The phase where choice re-enters the picture comes afterwards: structured review of complications such as heart or nerve involvement, rehabilitation after severe illness, follow-up testing and vaccination planning once the treating team confirms travel is medically appropriate. Personalised planning matters here, because a child recovering from throat diphtheria, an adult with possible toxin-related myocarditis and a family member exposed to a confirmed case each need different assessments and different follow-up.

Moving Forward After Diphtheria

Diphtheria is serious, but prompt treatment changes the course of the illness. The elements that matter most are early recognition, urgent medical evaluation, antitoxin when indicated, appropriate antibiotics, isolation, careful monitoring and disciplined follow-up. The features that concern clinicians most — a throat membrane, breathing difficulty, severe neck swelling, hoarseness, drooling, unexplained weakness or known exposure to a confirmed case — are the signs of an illness that progresses rather than one that waits, which is why care pathways for diphtheria are built around speed.

After the acute phase, recovery is a process: repeat cultures to confirm the bacteria have cleared, cardiac and neurological checks for delayed complications, rehabilitation where weakness lingers, and a vaccination review for the patient and the household. For most people, the longer-term picture is a return to school, work and travel after medical clearance — with up-to-date vaccination standing between them and a second encounter with the disease.

Frequently Asked Questions

What is diphtheria?

Diphtheria is a serious bacterial infection caused by toxin-producing strains of Corynebacterium diphtheriae. It most often affects the throat and upper airway, where a thick grey-white membrane can form, and the toxin released by the bacteria can injure the heart, nerves and kidneys. Because it can progress within days to airway narrowing and organ damage, clinicians treat suspected diphtheria as an emergency rather than waiting for laboratory confirmation.

How is diphtheria transmitted?

Diphtheria spreads mainly through respiratory droplets from coughing, sneezing and close face-to-face contact with an infected person. It can also spread through direct contact with infected skin sores in cutaneous diphtheria and, less commonly, through objects contaminated by secretions. Some people carry the bacteria in the nose or throat without feeling unwell and can still infect others, which is why public health teams trace and test close contacts of a confirmed case.

What are the symptoms of diphtheria?

Early symptoms resemble a sore throat with fever, malaise and swollen neck glands. Within days a firmly attached grey-white membrane may develop on the tonsils, throat or nose, causing painful swallowing, hoarseness and marked neck swelling. The membrane can bleed if disturbed and can obstruct breathing. Toxin effects may appear later as heart rhythm problems, weakness, difficulty swallowing or paralysis. Cutaneous diphtheria causes slow-healing skin ulcers.

How is diphtheria treated?

Treatment begins as soon as the diagnosis is suspected and combines diphtheria antitoxin to neutralise circulating toxin, antibiotics to clear the bacteria and stop further toxin production, strict isolation and close monitoring of the airway, heart and nervous system, often in hospital. Airway support may be needed if the membrane obstructs breathing. Close contacts are tested, given preventive antibiotics and offered vaccination. Recovery is followed by a booster dose.

Is diphtheria still a risk today?

Yes. Diphtheria has become rare in countries with strong childhood vaccination programmes, but it has not disappeared. The bacteria continue to circulate in parts of Asia, Africa, the Middle East, the Pacific and Eastern Europe, and outbreaks recur wherever vaccination coverage falls. Travellers, migrants and under-vaccinated people remain at risk, and because adult booster protection fades with time, adults in well-vaccinated countries are not automatically protected either.